{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:49Z","timestamp":1790623549998,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Forest Research Institute, Inc., an affiliate of Actavis Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40261-015-0318-2","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T13:26:22Z","timestamp":1440681982000},"page":"601-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects"],"prefix":"10.1007","volume":"35","author":[{"given":"Laishun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Boinpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayra","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wangsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Periclou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Ghahramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"318_CR1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","volume":"70","author":"AL Auclair","year":"2013","unstructured":"Auclair AL, Martel JC, Assi\u00e9 MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338\u201347.","journal-title":"Neuropharmacology."},{"key":"318_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.106.103382","volume":"318","author":"DC Deecher","year":"2006","unstructured":"Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657\u201365.","journal-title":"J Pharmacol Exp Ther."},{"key":"318_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.12m08141","volume":"74","author":"SA Montgomery","year":"2013","unstructured":"Montgomery SA, Mansuy L, Ruth A, et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74:363\u20139.","journal-title":"J Clin Psychiatry."},{"key":"318_CR4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/JCP.12m08197","volume":"74","author":"GM Asnis","year":"2013","unstructured":"Asnis GM, Bose A, Gommoll CP, et al. Efficacy and safety of levomilnacipran sustained release 40\u00a0mg, 80\u00a0mg, or 120\u00a0mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:242\u20138.","journal-title":"J Clin Psychiatry."},{"key":"318_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1503\/jpn.130040","volume":"39","author":"D Bakish","year":"2014","unstructured":"Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40\u00a0mg and 80\u00a0mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40\u20139.","journal-title":"J Psychiatry Neurosci."},{"key":"318_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/JCP.0000000000000060","volume":"34","author":"A Sambunaris","year":"2014","unstructured":"Sambunaris A, Bose A, Gommoll CP, et al. A phase III double-blind, placebo-controlled, flexible-dose study of levomilnacipran ER extended release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47\u201356.","journal-title":"J Clin Psychopharmacol."},{"key":"318_CR7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/21556660.2014.884505","volume":"3","author":"C Gommoll","year":"2014","unstructured":"Gommoll C, Greenberg W, Chen C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40\u2013120\u00a0mg\/day) in patients with major depressive disorder. J Drug Assess. 2014;3:10\u20139.","journal-title":"J Drug Assess"},{"key":"318_CR8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40261-013-0126-5","volume":"33","author":"R Mago","year":"2013","unstructured":"Mago R, Forero G, Greenberg WM, et al. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Invest. 2013;33:761\u201371.","journal-title":"Clin Drug Invest."},{"key":"318_CR9","first-page":"1","volume":"5","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Gommoll CP, Chen C, et al. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 2014;5:1\u20139.","journal-title":"CNS Spectr."},{"key":"318_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0000000000000033","volume":"29","author":"A Sambunaris","year":"2014","unstructured":"Sambunaris A, Gommoll C, Chen C, et al. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014;29:197\u2013205.","journal-title":"Int Clin Psychopharmacol."},{"key":"318_CR11","unstructured":"Forest Pharmaceuticals Inc. Fetzima\u00ae (levomilnacipran) extended-release capsules: U.S. Prescribing Information. Forest Pharmaceuticals, Inc.: St. Louis; 2013."},{"key":"318_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40261-014-0182-5","volume":"34","author":"L Chen","year":"2014","unstructured":"Chen L, Boinpally R, Greenberg WM, et al. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clin Drug Invest. 2014;34:351\u20139.","journal-title":"Clin Drug Invest."},{"key":"318_CR13","unstructured":"Forest Laboratories. Data on file. In vitro cytochrome P450 reaction phenotyping of F2695 in human liver microsomes. Xenotech Study Number: XT104114. 2011."},{"key":"318_CR14","unstructured":"Forest Laboratories. Data on file. Evaluation of human drug-metabolizing enzyme induction properties of F2695: in vitro experiments. Pierre Fabre M\u00e9dicament Study no CEPC 05-0173. 2006."},{"key":"318_CR15","unstructured":"Forest Laboratories. Data on file. Evaluation of human cytochrome P450 inhibitory properties of F2695: in vitro experiments. Pierre Fabre M\u00e9dicament Study no CEPC 05-0174. 2006."},{"key":"318_CR16","unstructured":"Forest Laboratories. Data on file. In vitro evaluation of F17400 as an inhibitor of cytochrome P450 (CYP) enzymes in human liver microsomes. XenoTech Study Number: XT105102. 2012."},{"key":"318_CR17","unstructured":"US Food and Drug Administration. Guidance for Industry: In-Vivo Drug Metabolism\/Drug Interaction Studies\u2014Study Design, Data Analysis, and Recommendations for Dosing and Labeling. 1999 Nov. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM072119.pdf . Accessed Mar 2010. Guidelines in use at time of study; guidelines subsequently amended: see Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf . Accessed October 2013."},{"key":"318_CR18","unstructured":"US Food and Drug Administration. Guidance for Industry, Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labeling. September, 2006. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM072119.pdf . No longer available online. Guidelines in use at time of study; guidelines subsequently amended: see Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, February 2012. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf . Accessed Dec 2013."},{"key":"318_CR19","unstructured":"International Conference on Harmonisation\u2014Efficacy (E2A), March 1995. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073087.pdf . Accessed July 2015."},{"key":"318_CR20","unstructured":"Pfizer, Inc. Xanax\u00ae XR CIV (alprazolam) extended-release tablets: U.S. Prescribing Information. Pfizer: USA: 2013."},{"key":"318_CR21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-3565(24)35228-0","volume":"291","author":"RB Kim","year":"1999","unstructured":"Kim RB, Leake B, Cvetkovic M, et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999;291:1204\u20139.","journal-title":"J Pharmacol Exp Ther."},{"key":"318_CR22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"EJ Wang","year":"2002","unstructured":"Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother. 2002;46:160\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"318_CR23","doi-asserted-by":"crossref","first-page":"P81","DOI":"10.1016\/j.clpt.2004.12.202","volume":"77","author":"PC Fernandez","year":"2005","unstructured":"Fernandez PC, Wallace DW, Ryan K, et al. Effects of oral ketoconazole on renal function in healthy volunteers. Clin Pharmacol Ther. 2005;77:P81.","journal-title":"Clin Pharmacol Ther."},{"key":"318_CR24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.clpt.6100431","volume":"84","author":"MO Magnusson","year":"2008","unstructured":"Magnusson MO, Dahl ML, Cederberg J, et al. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84:52\u201362.","journal-title":"Clin Pharmacol Ther."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0318-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0318-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0318-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:50:09Z","timestamp":1748584209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0318-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0318-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}